ADSL and neoplasm: Compared to anti‐PD‐L1 antibodies, synthetic PD‐L1 antagonist peptides also have higher stability, reduced immunogenicity, and lower production costs.[12] Additionally, peptides are easier to simulate the interaction between PD‐1 and PD‐L1 than small molecules.[6c] Obviously, the combination of AMPs and PD‐L1 antagonist peptides would further unleash the T cell anti‐tumor immunity.